Drug Profile
PP 1131
Alternative Names: P. aeruginosa phages cocktail - PHAXIAM Therapeutics; PHAGOBURN Pseudomonas phage therapy - PHAXIAM Therapeutics; PP-1131Latest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator Pherecydes Pharma
- Developer PHAXIAM Therapeutics
- Class Pseudomonas phages
- Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators; Cell membrane modulators; Cell wall modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Burn infections
Most Recent Events
- 26 Jun 2023 Pherecydes Pharma has merged with ERYtech Pharma to form PHAXIAM Therapeutics
- 05 Mar 2021 Discontinued - Phase-I/II for Burn infections in France, Belgium (Topical) (Pherecydes Pharma pipeline, March 2021)
- 16 Feb 2021 Pherecydes Pharma has patent protection for anti-Pseudomonas aeruginosa and anti-E. Coli phages in the US